Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab

PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) (212)Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal gro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Clin Oncol
Main Authors: Meredith, Ruby F., Torgue, Julien J., Rozgaja, Tania A., Banaga, Eileen P., Bunch, Patty W., Alvarez, Ronald D., Straughn, J. Michael, Dobelbower, Michael C., Lowy, Andrew M.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2018
Assuntos:
Original Articles: Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5449266/
https://ncbi.nlm.nih.gov/pubmed/27906723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000353
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados